Stock listing

OTC:GNVR Genvor Incorporated Stock

Follow Genvor Incorporated into a list and get an email when it puts out news.

Share price · OTC:GNVR

$0.26 USD -0.12 (-31.7%)

Close on Nov 20, 2026

Past year -84.7% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.233 – $0.28 USDNov 20, 2026
Volume
12,500 sharesNov 20, 2026
Market cap
$9.47M USDAt the close on Nov 20, 2026 · price × 36.41M shares outstanding
52-week range
$0.014 – $2.00 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$1,409 USDMedian day 100 shares · 32 days with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026
Genvor Incorporated logo

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · OTC:GNVR · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.26-0.121-31.7%$0.233$0.28$0.23312,500
$0.381+0.106+38.5%$0.381$0.381$0.381100
$0.275-0.025-8.4%$0.49$0.49$0.277,905
$0.30-0.45-60.0%$0.329$0.74$0.308,385
$0.750.000.0%$0.75$0.75$0.750
$0.750.000.0%$0.75$0.75$0.750
$0.750.000.0%$0.75$0.75$0.750
$0.750.000.0%$0.75$0.75$0.750
$0.750.000.0%$0.75$0.75$0.756
$0.750.000.0%$0.75$0.75$0.750
$0.750.000.0%$0.75$0.75$0.75970
$0.750.000.0%$0.75$0.75$0.750
$0.750.000.0%$0.75$0.75$0.750
$0.750.000.0%$0.65$0.75$0.6513,732
$0.750.000.0%$0.75$0.75$0.750
$0.750.000.0%$0.75$0.75$0.750
$0.750.000.0%$0.75$0.75$0.75100
$0.750.000.0%$0.75$0.75$0.750
$0.750.000.0%$0.75$0.75$0.750
$0.750.000.0%$0.75$0.75$0.750
$0.750.000.0%$0.75$0.75$0.750
$0.750.000.0%$0.75$0.75$0.750
$0.750.000.0%$0.75$0.75$0.750
$0.75+0.135+22.0%$0.64$0.75$0.641,662
$0.615-0.068-9.9%$0.615$0.615$0.615100
$0.6830.000.0%$0.683$0.683$0.6830
$0.683-0.218-24.2%$0.683$0.683$0.683100
$0.900.000.0%$0.90$0.90$0.900
$0.900.000.0%$0.90$0.90$0.900
$0.900.000.0%$0.90$0.90$0.900
$0.90+0.06+7.1%$0.72$0.90$0.72415
$0.84+0.09+12.0%$0.48$0.85$0.4827,785
$0.750.000.0%$0.75$0.75$0.750
$0.750.000.0%$0.75$0.75$0.750
$0.75-0.013-1.7%$0.75$0.75$0.75100
$0.7630.000.0%$0.763$0.763$0.7630
$0.763+0.000.0%$0.763$0.763$0.763100
$0.7630.000.0%$1.00$1.00$0.7631,115
$0.763-0.237-23.7%$1.00$1.00$0.763200
$1.000.000.0%$0.922$1.00$0.2012,300
$1.000.000.0%$1.00$1.00$1.000
$1.00+0.60+149.9%$1.00$1.00$1.00101
$0.40-0.083-17.1%$0.60$0.60$0.40300
$0.483-0.096-16.6%$0.513$0.60$0.402,685
$0.579-0.051-8.1%$0.548$0.579$0.5485,085
$0.63+0.12+23.5%$0.70$0.70$0.631,655
$0.51-0.18-26.1%$0.60$0.75$0.5130,603
$0.690.000.0%$0.69$0.69$0.690
$0.690.000.0%$0.69$0.69$0.690
$0.690.000.0%$0.69$0.69$0.69100
$0.690.000.0%$0.69$0.69$0.690
$0.690.000.0%$0.513$0.69$0.5131,500
$0.690.000.0%$0.69$0.69$0.693,350
$0.690.000.0%$0.69$0.69$0.69100
$0.690.000.0%$0.70$0.70$0.691,400
$0.690.000.0%$0.69$0.69$0.690
$0.690.000.0%$0.69$0.69$0.690
$0.69-0.01-1.4%$0.69$0.69$0.69100
$0.700.000.0%$0.68$0.70$0.682,800
$0.70-0.04-5.4%$0.70$0.70$0.70100
$0.740.000.0%$0.74$0.74$0.740
$0.740.000.0%$0.74$0.74$0.740
$0.74+0.43+138.5%$0.40$0.74$0.4010,050
$0.310.000.0%$0.31$0.31$0.311,000
$0.31-0.24-43.6%$0.40$0.40$0.314,500
$0.550.000.0%$0.55$0.55$0.550
$0.550.000.0%$0.55$0.55$0.550
Ticker
OTC:GNVR
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
OTC
Currency
USD

What changed lately

Latest news

All Genvor Incorporated news

Genvor Incorporated on 6ix

Sector
Health care
Industry
Biotechnology
News releases
14 in the last 12 months · 26 in all · newest Jul 27, 2026 · oldest 2023
Decks
1 deck · latest March 2026

Valuation

Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026

Enterprise value
$9.27M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
Negative equity
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
Negative equity
Beta vs S&P 500
0.44

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Genvor Incorporated · OTC:GNVRUS$9.47MUS$9.27Mn/an/an/an/an/an/a0.44
aTyr Pharma, Inc. · NASDAQ:ATYRUS$9.74M−US$28.09Mn/an/an/a0.3×n/a0.3×2.12
Lisata Therapeutics, Inc. · NASDAQ:LSTAUS$9.71M−US$273.0Mn/a−2,730×n/a1.3×n/a0.0×0.71
Purple Biotech Ltd. · TASE:PPBTUS$9.70MUS$3.73Mn/an/an/a0.8×n/a0.0×n/a
Jasper Therapeutics, Inc. · NASDAQ:JSPRUS$9.64M−US$125.6Mn/a−15.7×n/an/an/an/a2.02
Alzinova AB · OMXSTO:ALZUS$9.58MUS$8.35Mn/a17.0×n/a0.6×−484.4%0.0×n/a
Chemomab Therapeutics Ltd. · NASDAQ:CMMBUS$9.58MUS$4.92Mn/an/an/a2.6×n/a0.0×1.04
Poxel SA · EURONEXT:POXELUS$9.27MUS$73.95Mn/an/an/an/an/an/an/a
TScan Therapeutics, Inc. · NASDAQ:TCRXUS$9.27M−US$30.80Mn/a−5.9×n/a0.2×n/a0.9×1.66
Rapid Dose Therapeutics Corp · CSE:DOSEUS$9.13MUS$9.12Mn/a5.1×n/an/a−123.1%n/a0.64
CytoMed Therapeutics Limited · NASDAQ:GDTCUS$9.01MUS$8.23Mn/a14.7×n/a2.3×−730.3%0.1×0.16
Median of the othersUS$9.58MUS$4.33M−0.4×0.8×−484.4%0.0×1.04

Team and board

Officers

OfficerRole
Chad PawlakChief Executive Officer
Don KalkofenChief Financial Officer
Carly ScadutoDirector, Corporate Communications
Genvor IncorporatedInvestor Relations
George StavridesExecutive Vice President, Business Development & Commercialization – Agriculture
John M. ViglottiSVP Corporate Services
Brianna FochsSenior Scientist & Lab Manager
Clayton YatesCo-Founder
Jesse JaynesCo-Founder
Lance CulnaneDirector, AI & Machine Learning

Board

DirectorRole
Chad PawlakChief Executive Officer
Clayton YatesCo-Founder
Jesse JaynesCo-Founder

Decks

DeckKindSlidesDate
Investor Presentation (March 2026)Investor deck18 slidesMarch 2026

Open Decks

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2022FY2021FY2020FY2019
Revenue0000
Research and development455.9K240.3K00226.4K
Selling, general and administrative23.8K4.87K6.00K
Operating income-6.41M-2.78M-1.44M-3.10M
Depreciation and amortization1.38K1.83K1.83K1.83K
EBITDA-6.41M-2.78M-1.44M-3.10M
Interest expense59.8K17.7K43.8K102.8K
Income before tax-5.59M-2.88M-1.71M
Income tax0
Net income-5.59M-2.88M-1.71M-3.44M-23.8K-4.87K-6.00K
Earnings per share, basic-0.19-0.15-0.07-0.150.000.000.00
Earnings per share, diluted-0.22-0.15-0.07-0.150.000.000.00

Balance sheet

LineFY2025FY2024FY2023FY2022FY2022FY2021FY2020FY2019
Cash and equivalents37.2K37344.4K296.4K0000
Current assets45.8K21.7K66.3K298.4K536.0K225.7K
Property, plant and equipment13.9K15.7K17.6K18.9K19.4K
Total assets45.8K35.6K82.1K316.0K556.9K247.1K00
Accounts payable516.7K571.2K33.3K7.50K0
Current liabilities1.36M1.75M1.79M1.62M2.45M2.25M17.3K15.8K
Total debt20.0K904.5K1.32M1.14M
Total liabilities1.36M1.75M1.79M1.71M2.79M2.74M
Shareholders' equity-1.31M-1.71M-1.70M-1.39M-2.24M-62.5K-17.3K-15.8K
Shares outstanding30.2M20.0M19.1M38.7M26.0M24.0M20.0M20.0M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash from operations-555.7K-975.6K-871.7K-663.2K000
Cash from investing000
Cash from financing592.6K931.7K619.7K899.9K000
Change in cash36.9K-44.0K-252.0K236.6K00

Open Financials

Filings

FilingDateTypeFiled with
4 · Change in ownershipNov 20, 2026Insider tradeSEC
4 · Change in ownershipNov 3, 2026Insider tradeSEC
8-K · Current reportOct 26, 2026Material contractSEC
8-K · Current reportOct 19, 2026Material contractSEC
10-Q · Quarterly reportAug 14, 2026Quarterly reportSEC
DEF 14CJul 31, 2026Meeting noticeSEC
PRE 14CJul 20, 2026Meeting noticeSEC
8-K · Current reportJun 22, 2026Material contractSEC
3 · Initial statement of ownershipMay 26, 2026Insider tradeSEC
8-K · Current reportMay 21, 2026Management or board changeSEC
All 108 filings
FilingDateTypeFiled with
10-Q · Quarterly reportMay 13, 2026Quarterly reportSEC
8-K · Current reportMay 11, 2026FinancingSEC
8-K · Current reportApr 22, 2026Material contractSEC
4 · Change in ownershipApr 16, 2026Insider tradeSEC
4 · Change in ownershipApr 14, 2026Insider tradeSEC
10-Q/A · Quarterly report, amendedMar 13, 2026Quarterly reportSEC
10-Q · Quarterly reportFeb 12, 2026Quarterly reportSEC
4 · Change in ownershipJan 9, 2026Insider tradeSEC
10-K · Annual reportDec 10, 2025Annual reportSEC
DDec 5, 2025Other filingsSEC
4 · Change in ownershipDec 5, 2025Insider tradeSEC
3 · Initial statement of ownershipDec 5, 2025Insider tradeSEC
4 · Change in ownershipOct 9, 2025Insider tradeSEC
10-K/A · Annual report, amendedSep 9, 2025Annual reportSEC
10-Q · Quarterly reportSep 8, 2025Quarterly reportSEC
10-Q · Quarterly reportSep 8, 2025Quarterly reportSEC
8-K · Current reportSep 4, 2025Current reportSEC
10-Q · Quarterly reportAug 15, 2025Quarterly reportSEC
NT 10-Q · Late filing noticeAug 13, 2025Explanation requestSEC
10-K · Annual reportAug 1, 2025Annual reportSEC
10-K/A · Annual report, amendedJul 31, 2025Annual reportSEC
4 · Change in ownershipJul 3, 2025Insider tradeSEC
10-Q · Quarterly reportJun 30, 2025Quarterly reportSEC
4 · Change in ownershipJun 23, 2025Insider tradeSEC
4/A · Change in ownership, amendedJun 20, 2025Insider tradeSEC
4 · Change in ownershipJun 18, 2025Insider tradeSEC
DJun 17, 2025Other filingsSEC
NT 10-Q · Late filing noticeMay 12, 2025Explanation requestSEC
NT 10-Q · Late filing noticeFeb 18, 2025Explanation requestSEC
NT 10-K · Late filing noticeJan 31, 2025Explanation requestSEC
8-K · Current reportNov 13, 2024Management or board changeSEC
8-K · Current reportOct 22, 2024Management or board changeSEC
NT 10-Q · Late filing noticeAug 15, 2024Explanation requestSEC
8-K · Current reportMay 31, 2024Management or board changeSEC
10-Q · Quarterly reportMay 13, 2024Quarterly reportSEC
8-K · Current reportMar 20, 2024Current reportSEC
4 · Change in ownershipMar 18, 2024Insider tradeSEC
4 · Change in ownershipMar 18, 2024Insider tradeSEC
3 · Initial statement of ownershipMar 11, 2024Insider tradeSEC
4 · Change in ownershipFeb 16, 2024Insider tradeSEC
4 · Change in ownershipFeb 15, 2024Insider tradeSEC
10-Q · Quarterly reportFeb 14, 2024Quarterly reportSEC
8-K · Current reportJan 23, 2024Material contractSEC
8-K/A · Current report, amendedJan 18, 2024Current reportSEC
10-K · Annual reportJan 16, 2024Annual reportSEC
10-Q/A · Quarterly report, amendedJan 16, 2024Quarterly reportSEC
10-Q/A · Quarterly report, amendedJan 16, 2024Quarterly reportSEC
10-Q/A · Quarterly report, amendedJan 16, 2024Quarterly reportSEC
10-K/A · Annual report, amendedJan 16, 2024Annual reportSEC
8-K · Current reportJan 16, 2024Current reportSEC
NT 10-K · Late filing noticeJan 2, 2024Explanation requestSEC
3 · Initial statement of ownershipNov 14, 2023Insider tradeSEC
8-K · Current reportNov 6, 2023Material contractSEC
8-K · Current reportOct 10, 2023Material contractSEC
3 · Initial statement of ownershipSep 13, 2023Insider tradeSEC
8-A12G · Registration of a class of sharesAug 25, 2023Other filingsSEC
10-Q · Quarterly reportAug 9, 2023Quarterly reportSEC
8-K · Current reportJul 6, 2023Management or board changeSEC
10-Q · Quarterly reportApr 24, 2023Quarterly reportSEC
10-Q · Quarterly reportApr 24, 2023Quarterly reportSEC
10-K · Annual reportMar 28, 2023Annual reportSEC
10-Q/A · Quarterly report, amendedSep 1, 2022Quarterly reportSEC
10-Q · Quarterly reportAug 15, 2022Quarterly reportSEC
8-K · Current reportJul 1, 2022Meeting outcomeSEC
8-K · Current reportJun 15, 2022Current reportSEC
8-K · Current reportJun 9, 2022Acquisition or disposalSEC
10-Q · Quarterly reportApr 27, 2022Quarterly reportSEC
10-Q · Quarterly reportMar 29, 2022Quarterly reportSEC
10-K · Annual reportMar 21, 2022Annual reportSEC
424B3 · ProspectusNov 12, 2021Offer documentSEC
EFFECT · Notice that a registration is effectiveNov 12, 2021Other filingsSEC
CORRESP · Letter to the SECNov 1, 2021Other filingsSEC
POS AM · Amendment to an effective registrationOct 29, 2021Offer documentSEC
UPLOAD · Letter from the SECOct 5, 2021Other filingsSEC
POS AM · Amendment to an effective registrationSep 9, 2021Offer documentSEC
10-Q · Quarterly reportAug 23, 2021Quarterly reportSEC
10-Q · Quarterly reportAug 5, 2021Quarterly reportSEC
10-Q · Quarterly reportAug 5, 2021Quarterly reportSEC
10-K · Annual reportAug 2, 2021Annual reportSEC
10-Q · Quarterly reportJul 20, 2021Quarterly reportSEC
10-Q · Quarterly reportJul 20, 2021Quarterly reportSEC
8-K · Current reportFeb 1, 2021Material contractSEC
EFFECT · Notice that a registration is effectiveMay 14, 2020Other filingsSEC
CORRESP · Letter to the SECMay 13, 2020Other filingsSEC
S-1/A · Registration statement, amendedMay 4, 2020Offer documentSEC
UPLOAD · Letter from the SECMay 1, 2020Other filingsSEC
S-1/A · Registration statement, amendedApr 15, 2020Offer documentSEC
UPLOAD · Letter from the SECApr 6, 2020Other filingsSEC
S-1/A · Registration statement, amendedMar 19, 2020Offer documentSEC
UPLOAD · Letter from the SECMar 9, 2020Other filingsSEC
S-1/A · Registration statement, amendedFeb 21, 2020Offer documentSEC
8-K/A · Current report, amendedFeb 19, 2020Current reportSEC
8-K · Current reportFeb 13, 2020Material contractSEC
UPLOAD · Letter from the SECJan 21, 2020Other filingsSEC
S-1/A · Registration statement, amendedJan 7, 2020Offer documentSEC
S-1/A · Registration statement, amendedJan 2, 2020Offer documentSEC
UPLOAD · Letter from the SECDec 20, 2019Other filingsSEC
S-1 · Registration statementNov 21, 2019Offer documentSEC

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Genvor Incorporated’s releases · as of Aug 14, 2026

Common shares
36,410,120
Fully diluted
36,410,120

Fully diluted

LineSharesAs of
Common shares36,410,120Aug 14, 2026

Share count over time

CountShares
Aug 14, 202636,410,120

Open Cap table

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Brianna FochsSenior Scientist & Lab Manager · Since at least Nov 4, 2026
Carly ScadutoDirector, Corporate Communications · Since at least Jul 27, 2026
Chad Lee Pawlak SrChief Executive Officer, Director · Since at least Jan 17, 2024
Chad PawlakChief Executive Officer · Since at least Apr 16, 2026
Clayton YatesCo-Founder · Since at least Aug 25, 2023
Donald A KalkofenChief Financial Officer · Since at least May 18, 2026
Don KalkofenChief Financial Officer · Since at least Nov 4, 2026
Genvor IncorporatedInvestor Relations · Since at least Apr 17, 2026
George StavridesExecutive Vice President, Business Development & Commercialization – Agriculture · Since at least Jul 27, 2026
Jessee M JaynesChief Research Officer, Director · Since at least May 8, 2025
All 14 people
PersonSeat
Jesse JaynesCo-Founder · Since at least Jul 27, 2026
John M. ViglottiSVP Corporate Services · Since at least Dec 4, 2025
Judith Selene MillerChief Business Officer, Director · Aug 25, 2023 – Mar 15, 2024 · Past
Lance CulnaneDirector, AI & Machine Learning · Since at least Nov 4, 2026

Open People

Log in to ask 6ix AI your own questions about Genvor Incorporated.